All E. coli, Klebsiella pneumoniae, and Proteus mirabilis isolates with ceftriaxone MIC values >1 µg/mL were further screened at IHMA for extended-spectrum β-lactamase (ESBL) activity by using a disk diffusion assay testing cefotaxime (30 µg), cefotaxime/clavulanic acid (30/10 µg), ceftazidime (30 µg), and ceftazidime/clavulanic acid (30/10 µg) disks (BBL SensiDisc, Becton Dickinson, Franklin Lakes, NJ, USA). An isolate was confirmed as phenotypically ESBL positive if the inhibition zone diameter of the combination disk increased ≥5 mm, compared with that of only cephalosporin (1).
All isolates subjected to the phenotypic ESBL test were screened for the presence of β-lactamase genes encoding ESBLs (TEM-, SHV-, CTX-M-, VEB-, PER-, GES-type), originalspectrum β-lactamases (TEM-1, SHV-1, SHV-11), plasmid-mediated AmpC β-lactamases (ACC-, ACT-, CMY-, DHA-, FOX-, MIR-, MOX-type), and carbapenemases (KPC-, OXA-48-, IMP-, VIM-, NDM-, SPM-type) by using previously described multiplex PCR assays (2).
Enzyme variants were identified by DNA sequencing and comparison with sequences in public databases maintained by the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov) and the Lahey Clinic (www.lahey.org/studies). E. coli isolates with ceftriaxone MIC values >1 µg/mL were screened by PCR for the presence of sequence type 131-associated single-nucleotide polymorphisms in mdh and gyrB (3) and were screened separately for O25b-and O16-specific rfb variants (4). Sequence type 131 control strains were generously provided by D. Hoban and K. Nichol at the University of Manitoba (Winnipeg, Manitoba, Canada). Three E. coli isolates identified as ESBL producers at the Temple University site were not saved and sent to the IHMA laboratory but were confirmed to be ESBL by the Phoenix ESBL test (Becton Dickenson).
Audit Comparing Enrolled and Nonenrolled Cases
All sites conducted an audit to compare characteristics of enrolled and nonenrolled eligible patients. Site investigators screened emergency department (ED) patient logs to find patients with ED discharge of pyelonephritis (i.e., International Classification of Diseases, Ninth Revision, code 590.8 [pyelonephritis, unspecified] ) and a documented temperature >38.0 o C; they then reviewed medical records for these patients. Patients meeting study eligibility criteria had the following data collected: age, sex, ED disposition (i.e., discharged home, admitted to ward or ICU, admitted to ED observation, or left ED against medical advice), proportion pathogen and E. coli growth, and E. coli susceptibility to trimethoprim/sulfamethoxazole, ceftriaxone, and fluoroquinolones. 
